200,000+ products from a single source!
sales@angenechem.com
147402-53-7 | Isoxazole, 3-methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]- (9CI)
CAS No: 147402-53-7 Catalog No: AG00B3YM MDL No:
Product Description
Catalog Number:
AG00B3YM
Chemical Name:
Isoxazole, 3-methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]- (9CI)
CAS Number:
147402-53-7
IUPAC Name:
3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole
InChI:
InChI=1S/C9H14N2O/c1-7-6-9(12-10-7)8-4-3-5-11(8)2/h6,8H,3-5H2,1-2H3/t8-/m0/s1
InChI Key:
ILLGYRJAYAAAEW-QMMMGPOBSA-N
Properties
Complexity:
163
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
1
Defined Bond Stereocenter Count:
0
Exact Mass:
166.111g/mol
Formal Charge:
0
Heavy Atom Count:
12
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
166.224g/mol
Monoisotopic Mass:
166.111g/mol
Rotatable Bond Count:
1
Topological Polar Surface Area:
29.3A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.2
Literature
| Title | Journal |
|---|---|
| A comparative study of the effects of ABT-418 and methylphenidate on spatial memory in an animal model of ADHD. | Neuroscience letters 20121018 |
| [Stimulant and non-stimulant medication in current and future therapy for ADHD]. | Fortschritte der Neurologie-Psychiatrie 20120301 |
| Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity. | Journal of medicinal chemistry 20120126 |
| Synthesis of novel chiral Δ2-isoxazoline derivatives related to ABT-418 and estimation of their affinity at neuronal nicotinic acetylcholine receptor subtypes. | European journal of medicinal chemistry 20101201 |
| Extinction with varenicline and nornicotine, but not ABT-418, weakens conditioned responding evoked by the interoceptive stimulus effects of nicotine. | Neuropharmacology 20100601 |
| The enhancement of contextual fear conditioning by ABT-418. | Behavioural pharmacology 20100501 |
| Epiboxidine and novel-related analogues: a convenient synthetic approach and estimation of their affinity at neuronal nicotinic acetylcholine receptor subtypes. | Bioorganic & medicinal chemistry letters 20080815 |
| Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. | Biochemical pharmacology 20071015 |
| Dopamine release in human neocortical slices: characterization of inhibitory autoreceptors and of nicotinic acetylcholine receptor-evoked release. | Brain research bulletin 20060130 |
| Ligand selectivity for the acetylcholine binding site of the rat alpha4beta2 and alpha3beta4 nicotinic subtypes investigated by molecular docking. | Journal of medicinal chemistry 20050811 |
| Synthesis and alpha4beta2 nicotinic affinity of 2-pyrrolidinylmethoxyimines and prolinal oxime ethers. | Bioorganic & medicinal chemistry letters 20041206 |
| GABAergic systems modulate nicotinic receptor-mediated seizures in mice. | The Journal of pharmacology and experimental therapeutics 20030901 |
| Attentional effects of nicotinic agonists in rats. | Neuropharmacology 20030601 |
| Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. | The Journal of biological chemistry 20020419 |
| Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. | Behavioural brain research 20020401 |
| Non-stimulant treatment for Attention-Deficit/Hyperactivity Disorder. | Journal of attention disorders 20020101 |
| Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder. | Expert opinion on pharmacotherapy 20010401 |
| Health news. The sleeper syndrome. | Harvard health letter 20010101 |
| Genetic and pharmacological strategies identify a behavioral function of neuronal nicotinic receptors. | Behavioural brain research 20000801 |
| Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. | Psychopharmacology 19980301 |
| (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. | The Journal of pharmacology and experimental therapeutics 19940701 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.